ReposiTrak (TRAK) is a small-cap name with sparse sell-side attention, so no true multi-analyst consensus exists. The only verifiable target comes from Maxim Group analyst Tom Forte, who reiterated a $16 Buy rating on May 15, 2026. Because a single estimate cannot be averaged, the $16 level represents one published objective rather than a market-wide forecast. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The same analyst had carried a $29 target as recently as October 2025 before reducing it to $16 earlier in 2026. That adjustment reflected slower expected revenue growth and a more modest future P/E multiple, showing how quickly thin-coverage targets can change. Investors should view the $16 figure as one analyst’s perspective.
As of mid-November 2026, shares trade near $7.33, toward the lower end of the 52-week range between roughly $6.61 and $15.10. Reaching $16 would require an advance of about 118%, effectively reclaiming and moving slightly past the prior high.
The company posted modest but profitable results for fiscal 2026, with revenue rising about 3% to roughly $23.3 million and recurring revenue up about 4%. Net income came in near $7.6 million. The balance sheet shows approximately $27 million in cash and minimal debt, and the firm pays an annual dividend of $0.08 per share. Growth stays in the low single digits, however, and fourth-quarter revenue declined about 3% year over year due to earlier traceability work being pulled forward.
The main long-term driver remains the FDA’s food-traceability rule, which mandates end-to-end records for certain foods. ReposiTrak’s Traceability Network stands to benefit as retailers and suppliers prepare for compliance. Although enforcement has been delayed until July 20, 2028, management anticipates rising inquiry activity and faster traceability revenue growth as the deadline nears.
A second avenue is the “touchless retailing” initiative developed with SPAR, which management expects to contribute more meaningfully in 2027 and beyond. The business model features high gross margins, recurring subscription revenue, strong free-cash-flow conversion, and ongoing capital returns via dividends and preferred-share redemptions.
Execution remains the chief challenge. Revenue growth continues at a low-single-digit pace, and the most recent quarter showed a year-over-year decline partly due to a tough comparison. The extended FDA timeline could defer traceability revenue further, leaving the stock’s trailing P/E near 19 reliant on growth that has not yet materialized. With a market capitalization around $133 million and limited float, shares can move sharply in either direction, and thinly traded names sometimes lag fundamental improvements. Competition from larger supply-chain software providers is another factor to consider.
The $16 target lies just above the 52-week high of roughly $15.10, so any path higher first requires reclaiming a major resistance zone from the 2025 peak. Support lies near the 52-week low of about $6.61 and the recent low-to-mid $7 trading range. The $10 level represents the first psychological milestone a sustained recovery would need to clear before the $15-to-$16 area becomes realistic.
Analyst targets typically reflect a roughly 12-month horizon, though a single-target situation provides no measure of forecast dispersion. Investors should monitor quarterly results and guidance, especially any pickup in recurring and traceability revenue, progress on the SPAR touchless-retailing rollout, and management commentary on FDA compliance adoption. Capital-allocation decisions such as preferred-share redemptions and dividend adjustments, along with any change to the $16 target, also matter. Broader interest-rate moves and small-cap risk appetite can influence valuation multiples.
I occasionally reference Tickeron’s AI Daily Buy/Sell Signals when reviewing thinly covered names like this one, as the tool helps surface potential shifts in trend or momentum that complement traditional analysis.
In my own workflow, Tickeron’s AI Daily Buy/Sell Signals provide a practical way to track names with limited analyst coverage. The platform applies AI to scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals based on technical and market-condition changes. For a stock like ReposiTrak, where fundamental research is scarce, this kind of automated monitoring can highlight emerging opportunities or trend shifts more efficiently than manual review alone.
Whether ReposiTrak (TRAK) can reach $16 hinges on whether its traceability and touchless-retailing efforts produce faster revenue growth. The target originates from a single analyst rather than a broad consensus and would require a substantial move of roughly 118% that reclaims the 52-week high. A profitable, cash-generative, low-debt balance sheet and a clear regulatory catalyst provide support, yet slow growth, the recent quarterly revenue decline, and the delayed FDA timeline remain meaningful hurdles. With coverage this limited, evidence of sustained top-line acceleration matters more than the target itself.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Aroon Indicator for TRAK entered a downward trend on November 17, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 223 similar instances where the Aroon Indicator formed such a pattern. In 183 of the 223 cases the stock moved lower. This puts the odds of a downward move at 82%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TRAK as a result. In 67 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for TRAK turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 33 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRAK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
The RSI Indicator entered the oversold zone -- be on the watch for TRAK's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +7.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRAK advanced for three days, in 212 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
TRAK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.349) is normal, around the industry mean (-1.922). P/E Ratio (16.488) is within average values for comparable stocks, (9.599). Projected Growth (PEG Ratio) (0.140) is also within normal values, averaging (2.824). Dividend Yield (0.012) settles around the average of (0.071) among similar stocks. P/S Ratio (6.693) is also within normal values, averaging (71.013).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. TRAK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRAK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of proprietary software products
Industry PackagedSoftware